You are here: Industry Insights > NICE

News List

NICE advises restricted use of antibiotics for COPD pharmatimes
July 11, 2018
The National Institute for Health and Care Excellence is advising healthcare professionals to restrict use of antibiotics for chronic obstructive pulmonary disease (COPD).
NICE OKs three new therapies for blood cancer pharmatimes
July 09, 2018
Cost regulators for the NHS are recommending that three new types of treatment for people with blood cancer are made available on the NHS England and Wales.
NICE turns down BMS' blockbuster Opdivo for urothelial carcinoma pharmafile
July 06, 2018
Just in time for the NHS’ 70th birthday, UK watchdog NICE has announced that it has taken the decision to reject Bristol-Myers Squibb’s blockbuster immunotherapy drug Opdivo (nivolumab) for use on the health service in the treatment of locally advanced un
Final NICE no for BMS’ Opdivo in urothelial carcinoma pharmatimes
July 05, 2018
The National Institute for Health and Care Excellence has now issued final guidance rejecting NHS funding for use of Bristol-Myers Squibb’s Opdivo as a treatment for locally advanced unresectable or metastatic urothelial carcinoma (mUC).
MSD’s antiviral Prevymis fails to win NICE backing pharmatimes
July 05, 2018
MSD’s Prevymis has not won the support of NHS cost regulators for preventing cytomegalovirus (CMV) reactivation and disease in prone adults who have received an allogeneic haematopoietic stem cell transplant (HSCT).
NICE says Tookad too expensive for prostate cancer pharmatimes
July 04, 2018
The National Institute for Health and Care Excellence has concluded that Steba Biotech’s Tookad is not cost-effective enough to be approved enough for NHS funding to treat prostate cancer.
NICE ‘no’ for Roche’s Ocrevus in primary progressive MS pharmatimes
July 03, 2018
The National Institute for Health and Care Excellence has concluded that Roche’s Ocrevus should not be funded on the NHS for the treatment of primary progressive multiple sclerosis (PPMS) in adults.
NICE rejects adjuvant use of Perjeta post-surgery pharmatimes
June 21, 2018
The National Institute for Health and Care Excellence says adjuvant use of Roche’s breast cancer drug Perjeta in patients who have had surgery is not cost effective for the NHS.
NICE recommends MSD's Keytruda for advanced PD-L1-positive lung cancer pharmafile
June 07, 2018
UK drug watchdog NICE has chosen to issue final guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS for the treatment of previously untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adult patients.
NICE rules against first-line use of Ipsen’s Cabometyx pharmatimes
June 06, 2018
The National Institute for Health and Care Excellence has issued a preliminary decision rejecting first-line use of Ipsen/Exelixis’ Cabometyx in renal cancer on the NHS.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page